Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
Date:11/6/2009

DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® opthalmic solution on the first day following patent expiration. This strength of ketorolac is therapeutically equivalent to Acular® Ophthalmic Solution, 0.5%, from Allergan, Inc. Ketorolac tromethamine ophthalmic solution is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Acular® opthalmic solution has annual sales of approximately $40 million in the US.

Acular® is a registered trademark of Allergan, Inc.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recen
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
2. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
4. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
9. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), ... comments on the FDA panel meeting for non-thermal shortwave ... – Pulsed Shortwave Therapy Meeting was held on May ... USA.  The focus of the meeting was very narrow, ... focus solely on the application of non-thermal shortwave diathermy ...
(Date:5/23/2013)... May 23, 2013 Halozyme Therapeutics, Inc. ... appointment of David A. Ramsay ... most recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and ... working in our commercial group for the last ...
(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com .  A replay will be available on the ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Pfizer Inc. (NYSE: PFE ) today announced, at the ... the chronic low back pain and painful diabetic peripheral neuropathy studies in ... continues in some areas of high unmet medical need, including cancer pain. ... (Logo:   http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ...
... Heslin , MD of Bridge Street Medical Group will discuss use of health IT ... 20 , , , ... July 19 If a small general medical practice in ... health care for its patients, so can practices across the nation. That is the ...
Cached Medicine Technology:Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need 2Hudson Valley Physician Testifies Before House Health Subcommittee Tuesday About Incentives for Adoption of Health Information Technology 2Hudson Valley Physician Testifies Before House Health Subcommittee Tuesday About Incentives for Adoption of Health Information Technology 3
(Date:5/23/2013)... it when a woman harried by hot flashes says ... study published online in Menopause , the journal ... with objective tests that what these women say about ... studies showed that hot flashes were related to memory ... though there was a relationship between hot flashes and ...
(Date:5/23/2013)... Susquehanna Health is now a ... training course for adolescents age 11 and up. ... Dr. Patricia Keener after a colleague’s toddler choked to ... who didn’t know how to provide first aid. Safe ... medical basis that aims to reduce the number of ...
(Date:5/23/2013)... An anti-cancer drug about to be tested in a ... a possible treatment for Alzheimer,s disease has failed to ... plague Alzheimer,s patients, according to results of a study ... a professor of neuroscience affiliated with the Evelyn F. ... of Florida, emphasized the importance of verifying promising research ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
(Date:5/23/2013)... Former United States Vice President Dick Cheney served as ... Luncheon. , In front of 1,500 guests yesterday ... saying, "I am delighted to be here to have ... the Year Award. I think it's a tremendous recognition; ... a company like this because there are obviously a ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2
... this summer and a friend dares you to eat a raw ... hospital with a severe parasitic infection. Physicians at Washington University ... infection in six people who had consumed raw crayfish from streams ... years, but three have been diagnosed since last September; the latest ...
... ... statistics on the top-performing companies for the past six months, Jusuru International is the fastest ... ... has just released its statistics on the top-performing companies for the past six months, Jusuru ...
... Massachusetts Medical School report in the journal Nature Medicine ... malignant glioma, a pathway essential to the cancer,s ability ... that would stop the cancer,s ability to thrive. ... RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway ...
... infection improves patient outcomes, researchers say , TUESDAY, May ... ailment chronic obstructive pulmonary disease (COPD) do better when ... , COPD patients who were given antibiotics early in ... ventilation and less likely to have to be readmitted ...
... ... Version of Pearson Author Elana Zucker’s Best-selling Textbook, Being a Home Health Aide , ... Indianapolis, IN (PRWEB) May 25, 2010 ... decade, the Indiana Home and Hospice Care (IHHC) Foundation needed to quickly overhaul its outdated ...
... suggest that bacteria residing in the the human intestinal ... developing colon cancer. Scientists from the University of Florida ... of the American Society for Microbiology in San Diego, ... are more frequently detected in subjects with polyps, early ...
Cached Medicine News:Health News:Dangerous lung worms found in people who eat raw crayfish 2Health News:Dangerous lung worms found in people who eat raw crayfish 3Health News:Dangerous lung worms found in people who eat raw crayfish 4Health News:,Jusuru Tops New Company Launch Rankings, 2Health News:Novel RNA interference screening technique identifies possible path for malignant glioma treatment 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 3Health News:Indiana Home and Hospice Care Foundation Selects Pearson to Bolster Workforce Training Initiatives 2Health News:Indiana Home and Hospice Care Foundation Selects Pearson to Bolster Workforce Training Initiatives 3
... The FLU OIA test is a ... diagnosis of Influenza A and B with ... answer in just over 15 minutes. Assay ... specimen flexibility, and performance equivalent to 14-day ...
The CdTOX A OIA gets the results you need without specimen extraction or instrumentation. Results are available in minutes vs hours or days for EIA or other methods. The combination of performance, ...
... provides superior performance for the diagnosis ... that provides an answer in 6 ... will convince you of this tests ... deliver improved patient care with a ...
... for Botox therapy and nerve block ... injectable needle has a precisely machined ... with an attached 61-cm (24-in) lead ... insertion. Single patient use only. A ...
Medicine Products: